Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: CANCER ; SURVIVAL ; tumor ; Germany ; THERAPY ; TOXICITY ; FOLLOW-UP ; COHORT ; DRUG ; MONOCLONAL-ANTIBODY ; PATIENT ; murine ; colon ; treatment ; antibodies ; antibody ; GLYCOPROTEIN ; TRIAL ; COLON-CANCER ; MONOCLONAL-ANTIBODIES ; FLUOROURACIL ; folinic acid ; ONCOLOGY ; colon cancer ; overall survival ; ADJUVANT THERAPY ; SWITZERLAND ; methods ; PHASE ; monoclonal antibodies ; monoclonal antibody ; edrecolomab ; MONOCLONAL-ANTIBODY THERAPY ; stage II
    Abstract: Background: In a phase III study recruiting patients with stage II colon cancer the effect of adjuvant therapy with edrecolomab, a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, was compared to observation alone. Patients and Methods: From January 1997 until July 2000 a total of 377 patients were postoperatively stratified according to tumor stage (T3 vs. T4) and center, and randomly allocated to either treatment with edrecolomab ( cohort A, n = 183) or observation ( cohort B, n = 194). Patients in cohort A received a total of 900 mg edrecolomab. The study was terminated prematurely because of discontinuation of drug supply in Germany. Results: 305 patients were eligible for the primary endpoint of overall survival and 282 patients for disease-free survival. After a median follow-up of 42 months overall survival and disease-free survival were not significantly different. Toxicity was mild. Conclusions: In the present study, postoperative adjuvant treatment with edrecolomab in patients with resected stage II colon cancer did not improve overall or disease-free survival
    Type of Publication: Journal article published
    PubMed ID: 15933423
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: CANCER ; CANCER CELLS ; CELLS ; tumor ; CELL ; COMBINATION ; Germany ; IN-VIVO ; MICROSCOPY ; THERAPY ; VOLUME ; GENE ; gene therapy ; MICE ; ACTIVATION ; prognosis ; colon ; INJECTION ; treatment ; BREAST-CANCER ; PROMOTER ; genetics ; colorectal cancer ; COLORECTAL-CANCER ; chemotherapy ; CANCER-CELLS ; COLON-CANCER ; FLUORESCENCE ; GENE-THERAPY ; GREEN FLUORESCENT PROTEIN ; heredity ; CYP2B1 ; ifosfamide ; ACTIVATING CYTOCHROME-P450 ; cytochrome P450 ; ONCOLOGY ; colon cancer ; QUALITY-OF-LIFE ; ENZYME ; SULFATE ; HISTOLOGY ; COMPOUND ; CANCER-TREATMENT ; animal ; viability ; cytomegalovirus ; FORMULATION ; INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY ; ISOPHOSPHORAMIDE MUSTARD ; LAPAROSCOPIC FLUORESCENCE DIAGNOSIS ; peritoneal carcinomatosis ; TARGETED CHEMOTHERAPY
    Abstract: The prognosis of peritoneal spread from gastrointestinal cancer and subsequent malignant ascites is poor, and current medical treatments available are mostly ineffective. Targeted chemotherapy with intraperitoneal prodrug activation may be a beneficial new approach. L293 cells were genetically modified to express the cytochrome P450 enzyme 2B1 under the control of a cytomegalovirus immediate early promoter. This CYP2B1 enzyme converts ifosfamide to its active cytotoxic compounds. The cells are encapsulated in a cellulose sulfate formulation (Capcell(TM)). Adult Balb/c mice were inoculated intraperitoneally with 1 x 10(6) colon 26 cancer cells, previously transfected with GFP to emit a stable green fluorescence, by injection into the left lower abdominal quadrant. Two or five day's later animals were randomly subjected to either i.p. treatment with ifosfamide alone or ifosfamide combined with microencapsulated CYP2B1-expressing cells. Peritoneal tumor volume and tumor viability were assessed 10 days after tumor inoculation by means of fluorescence microscopy, spectroscopy and histology. Early i.p. treatment with ifosfamide and CYP2B1 cells resulted in a complete response. Treatment starting on day 5 and single-drug treatment with ifosfamide resulted in a partial response. These results suggest that targeted i.p. chemotherapy using a combination of a prodrug and its converting enzyme may be a successful treatment strategy for peritoneal spread from colorectal cancer
    Type of Publication: Journal article published
    PubMed ID: 16096652
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: CANCER ; EXPRESSION ; tumor ; carcinoma ; CELL ; Germany ; DISEASE ; DISEASES ; GENE ; GENES ; SAMPLE ; SAMPLES ; cell line ; TISSUE ; LINES ; PATIENT ; SERA ; ANTIGEN ; ANTIGENS ; SKIN ; CELL-LINES ; FREQUENCY ; FIELD ; FREQUENCIES ; RECOGNITION ; tumor antigens ; antibodies ; antibody ; TARGET ; colorectal cancer ; COLORECTAL-CANCER ; CELL-LINE ; LINE ; CANCER-PATIENTS ; CARCINOEMBRYONIC ANTIGEN ; RT-PCR ; IMMUNE-RESPONSE ; IMMUNOTHERAPY ; cancer-germline genes ; MAGE GENES ; MELANOMA PATIENTS ; NY-ESO-1 ; sero-reactivity ; TARGETS ; CANCER PATIENTS ; INTERFERON-GAMMA ; LOCATION ; CYTOLYTIC T-LYMPHOCYTES ; SERUM ; RECOMBINANT ; COLORECTAL-CARCINOMA ; TUMOR-ANTIGENS ; CARCINOMA PATIENTS ; CELL LYMPHOMA ; cTAGE ; GAGE ; MAGE
    Abstract: The expression of 14 individual and two groups of tumor antigens was characterized for colorectal carcinoma by RT-PCR using 26 colorectal carcinoma specimens, eight cell lines, six samples of patients with inflammatory bowl diseases, and nine specimens from different locations of an individual patient with a metastasized rectal carcinoma. The most frequently detected mRNAs were MAGE-A1 (58%), GAGE-3-7 (54%), and cTAGE-5a (31%). At medium frequencies (12-19%) we found cTAGE-1, MAGE-A2, se57-1, RAGE-4, and GAGE-1,2,8, while other tumor antigens were expressed rarely (〈9%). 85% of the samples were positive for at least one of the most frequently expressed antigens. Using a secondary SEREX approach and sera of eight colorectal cancer patients we found reactive antibodies against recombinant cTAGE-l (2 sera), se57-1 (2), truncated GAGE (1), and MAGE-Al (1). We conclude that certain cancer-germline genes can be detected in colorectal cancer and might therefore be promising targets for immunotherapy. (C) 2003 Elsevier Ltd. All rights reserved
    Type of Publication: Journal article published
    PubMed ID: 15142679
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Keywords: CANCER ; IRRADIATION ; Germany ; imaging ; DISEASE ; HISTORY ; DRUG ; SURGERY ; PATIENT ; treatment ; COMPUTED-TOMOGRAPHY ; ABNORMALITIES ; ANGIOGRAPHY ; SMALL-INTESTINE ; COMPLICATIONS ; INFLAMMATORY-BOWEL-DISEASE ; STENOSIS ; technique ; PUSH-ENTEROSCOPY ; DRUGS ; ENDOSCOPY ; BOWEL ; Crohn disease ; gastrointestinal bleeding ; jejunal stenosis ; wireless capsule enteroscopy
    Abstract: Wireless capsule enteroscopy, being a novel, painless investigative technique, is reported to be significantly superior to push enteroscopy in its ability to find bleeding abnormalities in the small intestine. Here we report a case of acute jejunal obstruction following wireless capsule endoscopy. The patient had a 1-month history of gastrointestinal bleeding of unknown source. Further evaluation including gastroscopy and colonoscopy, angiography and computed tomography (angio-CT), and radio-labeled erythrocytes scan failed to reveal a source of bleeding. Therefore, wireless capsule enteroscopy was performed. Before capsule endoscopy, there was no clinical or imaging evidence of strictures or stenosis. At readmission it could be shown that there were two inflamed strictures of the small intestine. The capsule was detected at a stricture of the small intestine detected by abdominal ultrasonography and conventional computed tomography. The patient underwent a medical treatment with steroidal and other anti-inflammatory drugs for a total of 23 days and was discharged without complaints. Acute laparotomy after readmission with jejunal ileus proofed the capsule occluding two highly inflamed jejunal stenosis caused by Crohn disease. The present case demonstrates the potential for complications when wireless capsule enteroscopy is performed in the presence of intestinal strictures. Any history of inflammatory bowel disease, abdominal irradiation, cancer, obstruction, and abdominal surgery must be elicited in detail and may exclude the use of wireless capsule enteroscopy
    Type of Publication: Journal article published
    PubMed ID: 16411112
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...